(Q28245689)

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Melioidosis: epidemiology, pathophysiology, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Melioidosis epidemiology and risk factors from a prospective whole-population study in northern Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Septicaemic melioidosis: a review of 50 cases from Malaysia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Risk factors for melioidosis and bacteremic melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

The epidemiology of melioidosis in Australia and Papua New Guinea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Melioidosis in 6 tsunami survivors in southern Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Melioidosis: Recrudescence Associated with Bronchogenic Carcinoma Twenty-six Years following Initial Geographic Exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Cerebral melioidosis in Singapore: a review of five cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Acute suppurative parotitis caused by Pseudomonas pseudomallei in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Prognostic significance of quantitative bacteremia in septicemic melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Role and significance of quantitative urine cultures in diagnosis of melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

A proposed scoring system for predicting mortality in melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Man-to-man transmission of melioidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Cystic Fibrosis and Burkholderia pseudomallei Infection: An Emerging Problem?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

In vitro activities of the newer beta-lactam and quinolone antimicrobial agents against Pseudomonas pseudomallei

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Susceptibility of Pseudomonas pseudomallei to new beta-lactam and aminoglycoside antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Activities of five new fluoroquinolones against Pseudomonas pseudomallei

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Postantibiotic effects and Burkholderia (Pseudomonas) pseudomallei: evaluation of current treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

A comparison of antibiotic susceptibility testing methods for cotrimoxazole with Burkholderia pseudomallei.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

beta-Lactamase of Pseudomonas pseudomallei and its contribution to antibiotic resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Cloning and expression of class A beta-lactamase gene blaA(BPS) in Burkholderia pseudomallei

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Cloning of the class D beta-lactamase gene from Burkholderia pseudomallei and studies on its expression in ceftazidime-susceptible and -resistant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Pseudomonas pseudomallei resistance to beta-lactam antibiotics due to alterations in the chromosomally encoded beta-lactamase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Burkholderia pseudomallei class a beta-lactamase mutations that confer selective resistance against ceftazidime or clavulanic acid inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

BpeAB-OprB, a multidrug efflux pump in Burkholderia pseudomallei

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

The Burkholderia pseudomallei BpeAB-OprB efflux pump: expression and impact on quorum sensing and virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Modified virulence of antibiotic-induced Burkholderia pseudomallei filaments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Highly resistant Burkholderia pseudomallei small colony variants isolated in vitro and in experimental melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Combination antimicrobial therapy of acute Burkholderia pseudomallei infection in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

A comparison of antibiotic regimens in the treatment of acute melioidosis in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Halving of mortality of severe melioidosis by ceftazidime

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Randomized, double-blind, controlled study of cefoperazone-sulbactam plus cotrimoxazole versus ceftazidime plus cotrimoxazole for the treatment of severe melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Comparison of imipenem and ceftazidime as therapy for severe melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Outcomes of patients with melioidosis treated with meropenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Oral fluoroquinolones for maintenance treatment of melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Out of hospital treatment of patients with melioidosis using ceftazidime in 24 h elastomeric infusors, via peripherally inserted central catheters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Serum bactericidal and inhibitory titres in the management of melioidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion for treatment of septicaemic melioidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Melioidosis: acute and chronic disease, relapse and re-activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Recurrent melioidosis in patients in northeast Thailand is frequently due to reinfection rather than relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

A double-blind placebo-controlled study of an infusion of lexipafant (Platelet-activating factor receptor antagonist) in patients with severe sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Early goal-directed therapy in the treatment of severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Intensive insulin therapy in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

Human-to-Human Transmission of Pseudomonas pseudomallei

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.3.445

21 January 2018

Identifiers

DOI

10.1586/14787210.4.3.445

1 reference

Consolidated OpenCitations Corpus – April 2017

2618079

2618079

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference